Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | Buy → Neutral | H.C. Wainwright | |
| 9/4/2024 | $9.00 | Buy | H.C. Wainwright |
| 10/24/2023 | $30.00 | Overweight | Cantor Fitzgerald |
6-K - Adlai Nortye Ltd. (0001944552) (Filer)
6-K - Adlai Nortye Ltd. (0001944552) (Filer)
20-F/A - Adlai Nortye Ltd. (0001944552) (Filer)
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago. Adlai Nortye has two abstracts scheduled for presentations at AACR. "We are pleased to present the progress of our innovative pipeline at the upcoming 2025 AACR Annual Meeting. We are especially proud of our R&D capabilities in designing and developing our multi-specific immune-oncology platf
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024. AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrop
H.C. Wainwright downgraded Adlai Nortye Ltd. from Buy to Neutral
H.C. Wainwright initiated coverage of Adlai Nortye Ltd. with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald initiated coverage of Adlai Nortye Ltd. with a rating of Overweight and set a new price target of $30.00
SC 13G - Adlai Nortye Ltd. (0001944552) (Subject)
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Resear